Abstract:New analogs of vitamin D3. Calcitriol, the most active metabolite of vitamin D, controls parathyroid gland growth and suppresses the synthesis and secretion of parathyroid hormone (PTH). However, because of its potent effects on intestinal calcium absorption and bone mobilization, calcitriol treatment can induce hypercalcemia, often precluding its use at therapeutic doses. Hyperphosphatemia is also a persistent problem among patients undergoing chronic hemodialysis and can be aggravated by therapeutic doses of calcitriol. Several pharmaceutical companies were able to modify the side-chain of the 1,25(OH)2D3, allowing some of these new analogs to retain the action on the parathyroid glands while decreasing their hypercalcemic and hyperphosphatemic effects. The structure-activity relationship for ligand-mediated transcriptional regulation has been studied in detail. In some analogs the serum binding protein (DBP) plays a key role in determining the pharmacokinetics of the vitamin D compound. The affinity to DBP for 22-oxacalcitriol (OCT), an analog of calcitriol for the treatment of secondary hyperparathryoidism, is approximately 300–400 times lower than that of calcitriol and the analog is rapidly cleared from the circulation. The mechanisms for the selectivity of 19-nor-1,25(OH)2D2 (paricalcitol) (Zemplar®) another analog of calcitriol, is clearly different from OCT. Although the mechanisms of action is not completely known, it does appear that paricalcitol down-regulates the VDR in the intestine. It is likely that the unique biological profiles of vitamin D analogs in vivo are due to multiple mechanisms. Understanding the molecular basis of the analog selectivity will not only provide an explanation for their unique actions but allow intelligent design of more effective analogs in the future.

First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

Design, Synthesis, Evaluation and Structure of Allenic 1α,25-Dihydroxyvitamin D3 Analogs with Locked Mobility at C-17

Design, synthesis, and biological activity of D-bishomo-1α,25-dihydroxyvitamin D 3 analogs and their crystal structures with the vitamin D nuclear receptor

Investigation of 20S-Hydroxyvitamin D3 Analogs and Their 1Α-Oh Derivatives As Potent Vitamin D Receptor Agonists with Anti-Inflammatory Activities

Chemical synthesis, biological activities and action on nuclear receptors of 20S(OH)D3, 20S,25(OH)2D3, 20S,23S(OH)2D3 and 20S,23R(OH)2D3

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds

1Α,20s-Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis

Vitamin D Analogs: Mechanism of Action and Therapeutic Applications

Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs.

Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity.

4-Hydroxy-1α,25-Dihydroxyvitamin D3: Synthesis and Structure–Function Study

Synthesis of an Antitumoral Diarylheptanoid Containing 1,3-Diol Functionality

Synthesis of 1 Α, 25-Dihydroxyvitamin D3

Chemical Synthesis and Biological Activities of 20S,24s/r-Dihydroxyvitamin D3 Epimers and Their 1Α-Hydroxyl Derivatives

Vitamin D analogs: Therapeutic applications and mechanisms for selectivity

Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton

Total Synthesis of Biologically Active 20S-Hydroxyvitamin D3

Structural Development of Silicon-Containing Retinoids: Structure-Activity Relationship Study of the Hydrophobic Pharmacophore of Retinobenzoic Acids Using Silyl Functionalities

Synthesis and Biological Evaluation of Vitamin D3 Metabolite 20S,23s-Dihydroxyvitamin D3 and Its 23r Epimer

New analogs of vitamin D3